A glimmer of hope emerges for those battling glioblastoma, the aggressive brain cancer. Dr. Dimitris G. Placantonakis from NYU Langone Health’s Perlmutter Cancer Center is leading a groundbreaking clinical trial for sonodynamic therapy. Unlike traditional methods, this noninvasive treatment exploits ultrasound-induced luminescence to target cancer cells.
Participants in the study will receive 5-aminolevulinic acid (5-ALA) infusion and focused ultrasound waves to trigger light emission within cancer cells, generating free radicals that can damage and destroy them. What’s truly remarkable is that this technique eliminates the need for invasive surgery, minimizing risks and potential side effects.
The study’s two-phase approach aims to establish safety and effectiveness. Phase 1, already enrolling participants, seeks to prove the safety of sonodynamic therapy, while Phase 2 will assess its efficacy with a larger participant pool and maximum tolerated ultrasound energy.
This innovative trial sparks optimism, offering new possibilities to extend survival for those with recurrent or progressive glioblastoma. Kudos to the dedicated researchers and medical professionals pushing the boundaries of science to bring hope to those who need it most!
Source & Original Story: NYU Langone Health